Table 1.
Patient Characteristics During KSHV-MCD Activity and Remissiona
| Characteristic | Active Disease (n = 19) | Remission (n = 21)b |
|---|---|---|
| Symptomatic disease, No. (%) | 16 (84) | 0 |
| Symptoms present, No.c | 4 (0–10) | 0 |
| CTCAE grade for most severe symptomd | 2 (0–4) | NA |
| ECOG performance status | 1 (0–2) | 0 (0–1) |
| Temperature, °C | 36.8 (35.9–39.5) | 36.3 (35.3–37.2) |
| Hemoglobin, g/dL | 10.1 (8.0–14.4) | 12.9 (10.3–15.0) |
| Platelet count, 103 cells/µL | 155 (25–567) | 201 (118–438) |
| Leukocyte count, 103 cells/µL | 5.3 (1.0–15.7) | 4.4 (1.8–10.9) |
| Sodium, mmol/L | 136 (126–139) | 137 (135–142) |
| Albumin, g/dL | 2.8 (1.7–4.0) | 4.1 (3.5–4.5) |
| C-reactive protein, g/dL | 16 (0.7–211) | 3.8 (<0.3–14.0) |
| KSHV viral load, copies/106 PBMCs | 4545 (0–585 714) | 0 (0–2848) |
| Receiving ART, No. (%) | 19 (100) | 21 (100) |
| HIV viral load, copies/mL | <50 (<50–7710) | <50 (<50–2781) |
| HIV viral load undetectable (<50 copies/mL), No. (%) | 13 (68) | 19 (90) |
| CD4 cell count, cells/µL | 286 (67–1319) | 380 (139–841) |
Abbreviations: ART, antiretroviral therapy; CTCAE, National Cancer Institute Common Toxicity Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; KSHV, Kaposi sarcoma herpesvirus; KSHV-MCD, KSHV-associated multicentric Castleman disease; NA, not applicable; PBMCs, peripheral blood mononuclear cells.
a Unless otherwise noted, values represent medians (ranges).
b Any abnormalities noted during remission were not attributable to KSHV-MCD.
c All clinical symptoms attributable to KSHV-MCD, including fever but not laboratory abnormalities.
d Most severe symptom attributable to KSHV-MCD.